Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $9.13 | N/A |
Market Cap | $451.10M | N/A |
Shares Outstanding | 49.41M | 0.00% |
Employees | 0 | N/A |
Shareholder Equity | 164.63M | 31.12% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 15.45 | N/A |
P/S Ratio | 8.50 | N/A |
P/B Ratio | 2.74 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.1259 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $53.04M | N/A |
Earnings | $20.73M | N/A |
EPS | 0.591 | N/A |
Earnings Yield | 0.0647 | N/A |
Gross Margin | 0.8878 | N/A |
Operating Margin | 0.5631 | N/A |
Net income margin | 0.3908 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $131.20M | N/A |
Total Debt | $677.18K | N/A |
Cash on Hand | $106.20M | N/A |
Debt to Equity | 0.1196 | 20.61% |
Cash to Debt | $156.83 | 62.18% |
Current Ratio | $7.44 | -27.35% |